The latest News Headlines from the Scientific, Research and HighTech world

Články z PhysOrgErlotinib dosing in lung cancer depends on smoking status

13. 1 2010 (05:50)

Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.